About Zinc finger and SCAN domain-containing protein 9
Zinc finger and SCAN domain-containing protein 9 (ZSCAN9) is a protein
from Homo sapiens identified by UniProt accession
O15535, 394 residues long.
MolForge cross-references it against 0 known binders and
89 disease associations.
Target properties
| Protein name | Zinc finger and SCAN domain-containing protein 9 |
| UniProt accession | O15535 |
| Gene | ZSCAN9 |
| Organism | Homo sapiens |
| Length | 394 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (89)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.22
- Red cell distribution width · score 0.21
- autism spectrum disorder · score 0.21
- type 1 diabetes mellitus · score 0.17
- reticulocyte count · score 0.16
- unipolar depression · score 0.11
- bipolar disorder · score 0.10
- mean corpuscular volume · score 0.10
- reticulocyte measurement · score 0.10
- hemoglobin measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15535-F1 | alphafold | PREDICTED | 63.72 | — |
Amino-acid sequence (394 residues)
MNTNSKEVLS LGVQVPEAWE ELLTMKVEAK SHLQWQESRL KRSNPLAREI FRRHFRQLCY QETPGPREAL TRLQELCYQW LRPHVSTKEQ ILDLLVLEQF LSILPKELQG WVREHCPESG EEAVILLEDL ERELDEPQHE MVAHRHRQEV LCKEMVPLAE QTPLTLQSQP KEPQLTCDSA QKCHSIGETD EVTKTEDREL VLRKDCPKIV EPHGKMFNEQ TWEVSQQDPS HGEVGEHKDR IERQWGNLLG EGQHKCDECG KSFTQSSGLI RHQRIHTGER PYECNECGKA FSRSSGLFNH RGIHNIQKRY HCKECGKVFS QSAGLIQHQR IHKGEKPYQC SQCSKSYSRR SFLIEHQRSH TGERPHQCIE CGKSFNRHCN LIRHQKIHTV AELV
Explore Zinc finger and SCAN domain-containing protein 9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets